American Urological Association

The Urology Care Foundation Encourages Men to Take Charge of Their Health, One Checkup at A Time, For Men’s Health Month

Retrieved on: 
пятница, мая 31, 2024
Peyronie's disease, Disease, Diabetes, Cardiovascular disease, American Urological Association, UCHealth, AUA, Urology, Prostate cancer, Diagnosis, Male, Testosterone, Health, Life, Cancer, Testicular cancer, Vasectomy, Semen analysis, Education minister, Erectile dysfunction, Infertility, BPH, System, Incontinence

BALTIMORE, May 31, 2024 (GLOBE NEWSWIRE) -- June starts Men’s Health Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is encouraging men to take charge of their health, one checkup at a time.

Key Points: 
  • BALTIMORE, May 31, 2024 (GLOBE NEWSWIRE) -- June starts Men’s Health Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is encouraging men to take charge of their health, one checkup at a time.
  • But cancers are not the only urological issues men should be getting checked out; for men, urology includes the entire urinary tract and reproductive organs.
  • Once these problems are diagnosed, men can partner with a men's health specialist to get things back on the right track.
  • For more information on all aspects of men’s health, view the Urology Care Foundation’s Men’s Health Month Info Center.

AUA Announces 2024-2025 H. Logan Holtgrewe Legislative Fellow

Retrieved on: 
четверг, мая 30, 2024
Patient, American Urological Association, Brandeis University, AUA, National Rural Health Association, Brigham Young, Jefferson Health, Anatomy, Medicine, Public policy, Brigham Young University, Health policy, Chronic pain, Paul Ambrose, Nursing

BALTIMORE, May 30, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) today announced that Jacob Thatcher, DO, has been named the 2024-2025 H. Logan Holtgrewe Legislative Fellow.

Key Points: 
  • BALTIMORE, May 30, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) today announced that Jacob Thatcher, DO, has been named the 2024-2025 H. Logan Holtgrewe Legislative Fellow.
  • As the AUA’s Holtgrewe Fellow, Dr. Thatcher will complete a six-week fellowship with a legislative office in Washington, DC, and participate in major AUA advocacy initiatives, including the Annual Urology Advocacy Summit and meetings of the AUA’s Public Policy Council and Legislative Affairs Committee.
  • Jacob Thatcher personifies all the traits the selection committee hopes for in a Holtgrewe Fellow.
  • The Holtgrewe Fellowship program was established in recognition of Dr. H. Logan Holtgrewe, former AUA president and past chairman of the AUA’s Health Policy Council.

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Retrieved on: 
четверг, мая 30, 2024
Technology, Health Technology, Software, Other Health, Biotechnology, Health, Science, Oncology, Artificial Intelligence, Other Science, Uncertainty, Patient, Doctor of Philosophy, General partnership, American Urological Association, AUA, Bladder cancer, H&E, Neoplasm, Disease, Histology, Publication, AI, Cancer, Biomarker, Pear VC, Labs, Valar in Middle-earth, BCG, Abstract, CHAI, Physician, Annual general meeting

Valar Labs , the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing.

Key Points: 
  • Valar Labs , the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing.
  • The funding follows Valar Labs’ completion of a recent international, multi-institution validation study and subsequent launch of Vesta, the first AI-based diagnostic test to predict response to first line treatment in bladder cancer.
  • And bladder cancer is only the beginning; we can’t wait to see where they take the technology next.”
    Valar Labs was founded to reduce uncertainty in cancer treatment decisions.
  • “Valar Labs could transform how we approach cancer treatment decisions for a large number of patients today,” said Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Retrieved on: 
пятница, мая 17, 2024
Infectious Diseases, FDA, Entertainment, Clinical Trials, Biotechnology, Health, Pharmaceutical, Oncology, Podcast, Partnership, Patient, American Urological Association, News, AUA, Bladder cancer, NK, Bacillus, University, MD Anderson Cancer Center, SII, Research, Cancer, MHC, CIS, BCG, NMIBC, MBBS, Annual general meeting, Vaccine

“The reports that BCG induces loss of MHC has only been recently discovered, resulting in progression of the cancer with cancer immune evasion from the T cells.

Key Points: 
  • “The reports that BCG induces loss of MHC has only been recently discovered, resulting in progression of the cancer with cancer immune evasion from the T cells.
  • These MHC-negative cells are the exact target for natural killer cells which ANKTIVA activates.
  • ANKTIVA, a first-in-class IL-15 receptor agonist, received approval from the FDA on April 22 for the treatment of patients with BCG-unresponsive NMIBC CIS.
  • ANKTIVA’s unique mechanism of action activates the body’s natural killer cells and killer T-cell immune system to attack tumor cells.

Study Presented at AUA Shows Superior Kidney Stone Clearance Rates for SURE Procedure Using Calyxo’s CVAC System vs Standard URS

Retrieved on: 
вторник, мая 14, 2024
Medical Devices, Health, Science, Research, Health Technology, URS, Gold, Patient, Kidney, Doctor of Philosophy, Karger Publishers, American Urological Association, Kidney stone disease, AUA, CVAC, University, Urology, Safety, Hospital, MD, Physician, SURE, Ureteroscopy, Pharmaceutical industry

The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco.

Key Points: 
  • The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco.
  • In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS.
  • Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden.
  • “Based on our study results, the SURE procedure was determined to be a safe kidney stone treatment that delivers consistently higher stone clearance and lower residual stone volume when compared with URS,” reported Dr. Chi.

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

Retrieved on: 
понедельник, мая 13, 2024
Health, Hospitals, Clinical Trials, General Health, Pharmaceutical, Biotechnology, New Drug Application, Mitomycins, Patient, Medicare, American Urological Association, Investment, AUA, Food, NDA, Recurrence, FDA, IND, Safety, Conference, Gesellschaft mit beschränkter Haftung, Growth, IP, LG, ATLAS, DFS, Software, Research, RTW, Webcast, Cancer, Annual general meeting, Pharmaceutical industry

The company plans to complete the submission in Q3 2024 with a potential FDA decision as early as the first quarter of 2025.

Key Points: 
  • The company plans to complete the submission in Q3 2024 with a potential FDA decision as early as the first quarter of 2025.
  • A soon-to-be-published post-hoc analysis of the OLYMPUS trial assessed the long-term effects in treating LG-UTUC with JELMYTO.
  • The results show that JELMYTO treatment demonstrated favorable recurrence free survival rates for patients with LG-UTUC who respond to initial induction.
  • JELMYTO Revenue: JELMYTO net product revenues were $18.8 million and $17.2 million for the three months ended March 31, 2024 and 2023, respectively.

Rigicon Announces Groundbreaking Advances in Prosthetic Urology with ContiReflex® and Testi10 Testicular Prosthesis

Retrieved on: 
понедельник, мая 13, 2024
Testament, Patient, Survival, PRB, American Urological Association, Health, AUA, Male, Erectile dysfunction, Safety, Stress incontinence, Anatomy, Patient safety, Canadian International Council, Research, Survival rate, Publishing, Quality of life, Multimedia, Pharmaceutical industry

RONKONKOMA, N.Y., May 12, 2024 /PRNewswire-PRWeb/ -- Rigicon Inc., a pioneering medical device company, today announced significant advancements in its ContiReflex® artificial urinary sphincter and Testi10TM testicular prosthesis lines, showcased in recent high-profile scientific forums.

Key Points: 
  • In a significant stride for urological health, Rigicon Inc. proudly announces groundbreaking enhancements to its ContiReflex® artificial urinary sphincter and Testi10 testicular prosthesis.
  • Meanwhile, the Testi10 testicular prosthesis sets a new standard in prosthetic reliability and patient safety, achieving a remarkable 99.8% survival rate over 54 months.
  • Rigicon's commitment to innovation and patient care continues to redefine industry standards and improve the quality of life for patients globally.
  • Rigicon's Testi10 testicular prosthesis has been recognized for its exceptional reliability and safety in a comprehensive study published in the International Journal of Impotence Research.

Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum

Retrieved on: 
понедельник, мая 6, 2024
Congress, Society, Interventional radiology, Mayo Clinic, Urology, Safety, American Urological Association, Poster, American Roentgen Ray Society, TSX, Prostate cancer, Prostate, Salvage therapy, Abdominal Radiology, Patient, ARRS, AUA, ECR, Clinical trial, SIR, Annual general meeting, JUA, BPH, Turku University Hospital, EAU

TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, is pleased to announce that a total of 25 paper, poster and podium presentations highlighting the Transurethral Ultrasound Ablation (“TULSA”) procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer and/or benign prostatic hyperplasia (“BPH”) patients have been made at major medical meetings already in 2024.

Key Points: 
  • “The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U.S. commercial centers, such as Mayo Clinic in Florida, Busch Center in Georgia, and UT Southwestern Medical Center in Texas, as well as international user sites, like Sapporo Hokuyu Hospital in Japan, ALTA Klinik in Germany, and Turku University Hospital in Finland, add to the growing body of evidence supporting the potential of TULSA as a mainstream treatment for prostate disease,” said Arun Menawat, Profound’s CEO and Chairman.
  • “The various presentations made at AUA and other major medical conferences have highlighted TULSA’s clinical use across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and BPH; to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer,” added Dr. Menawat.
  • “Importantly, real-world data from top institutions is also consistently demonstrating similar outcomes to the TACT FDA regulatory study.
  • We would like to take this opportunity to thank the many esteemed researchers and clinicians who have contributed to the growing awareness of TULSA among urologists, both at home and abroad, and look forward to continuing to build on that positive momentum as the year progresses.”

Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia

Retrieved on: 
понедельник, мая 6, 2024
FDA, Bleeding, Safety, Risk, American Urological Association, Abstract, LUTS, ASC, Surgeon, TURP, International Prostate Symptom Score, Patient, SDD, AUA, Health, Patient satisfaction, Clinical trial, SAN, BPH, IPSS, Benign prostatic hyperplasia

The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas.

Key Points: 
  • The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas.
  • “The data presented at AUA confirm the safety and long-term durability of Aquablation therapy in treating men with symptomatic benign prostatic hyperplasia, regardless of prostate size or shape," said Reza Zadno, CEO of PROCEPT BioRobotics.
  • Three surgeons at Potomac Urology collected data on 812 consecutive men treated with Aquablation therapy.
  • We have treated more than 800 men with Aquablation therapy and feel that the results truly speak for themselves,” said Shawn Marhamati, MD, MS, at Potomac Urology.

Studies Show Diabetes Medicine Can Cause Urologic Complications

Retrieved on: 
воскресенье, мая 5, 2024
Urine, Risk, American Urological Association, Abstract (summary), Abstract, MD, Research, Attention, Patient, Kidney, Albany Medical Center, Cardiovascular disease, Glucose, Annual general meeting, Chronic kidney disease, Urinary tract infection, SAN, Heart failure, Pharmaceutical industry

Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering important updates on diabetes medicine and urologic complications in San Antonio, Texas, from May 3 to 6.
  • “These meds are increasingly popular due to their ability to lower cardiovascular events and the risk of end stage renal disease.
  • They are now first line therapies for diabetes management in patients with cardiovascular disease, chronic kidney disease and heart failure,” said Dr. Inouye.
  • All three of these talks discuss the urologic sequelae we see in our clinics.”
    The following abstracts are covered in the moderated panel: